Matthew P. Patricelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthew P. Patricelli has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin D. Horning
Vividion Therapeutics, San Diego, California
27 shared publications - Todd M. Kinsella
Vividion Therapeutics, San Diego, USA
26 shared publications - David S. Weinstein
Vividion Therapeutics, San Diego, California
25 shared publications - Gabriel M. Simon
Vividion Therapeutics, San Diego, California 92121, United States
25 shared publications - John J. Sigler
Vividion Therapeutics, San Diego, California
25 shared publications - Justine Lu
Vividion Therapeutics, San Diego, California
25 shared publications
Latest Publications
- Open Access
Allosteric covalent inhibition of cereblon through cryptic cysteine targeting
Thalidomide-derived cereblon (CRBN) modulators are among the most clinically impactful targeted protein degradation therapeutics, redirecting the CRL4-CRBN E3 ubiquitin ligase to degrade disease-driving neosubstrates. All current CRBN-targeting IMiDs and CELMoDs engage a single orthosteric pocket, leaving CRBN’s conformational landscape largely unexploited pharmacologically. Using cysteine-directed chemoproteomic screening, we identified covalent ligands that engage Cys287, a cryptic allosteric pocket distal to the orthosteric site. Our lead compound, VVD-105917, acts as a pan-inhibitor of IMiD/CELMoD-driven neosubstrate degradation. Cryo-EM structures reveal that covalent Cys287 engagement traps CRBN in its open, inactive conformation, resolving a previously unobserved N-terminal segment and sensor loop. Sequential incubation experiments show the conformational outcome depends on ligand addition order, demonstrating that even potent CELMoD-driven closure can be overridden by allosteric engagement. A recently reported ligand at this same pocket produces the opposite effect, promoting rather than blocking closure, indicating the Cys287 site is mechanistically sign-switchable. These findings establish covalent chemoproteomics as a strategy for discovering and controlling E3 ligase conformational switches.
Open AccessAllosteric covalent inhibition of cereblon through cryptic cysteine targeting
Thalidomide-derived cereblon (CRBN) modulators are among the most clinically impactful targeted protein degradation therapeutics, redirecting the CRL4-CRBN E3 ubiquitin ligase to degrade disease-driving neosubstrates. All current CRBN-targeting IMiDs and CELMoDs engage a single orthosteric pocket, leaving CRBN’s conformational landscape largely unexploited pharmacologically. Using cysteine-directed chemoproteomic screening, we identified covalent ligands that engage Cys287, a cryptic allosteric pocket distal to the orthosteric site. Our lead compound, VVD-105917, acts as a pan-inhibitor of IMiD/CELMoD-driven neosubstrate degradation. Cryo-EM structures reveal that covalent Cys287 engagement traps CRBN in its open, inactive conformation, resolving a previously unobserved N-terminal segment and sensor loop. Sequential incubation experiments show the conformational outcome depends on ligand addition order, demonstrating that even potent CELMoD-driven closure can be overridden by allosteric engagement. A recently reported ligand at this same pocket produces the opposite effect, promoting rather than blocking closure, indicating the Cys287 site is mechanistically sign-switchable. These findings establish covalent chemoproteomics as a strategy for discovering and controlling E3 ligase conformational switches.
- Open Access
- 29 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (11) , 4068-4078
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial
Werner syndrome helicase (WRN) is a synthetic lethal target for microsatellite instability (MSI) cancers. In part 1 of this ongoing first-in-human, phase 1 trial, escalating doses of RO7589831 (VVD-133214), a first-in-class, WRN covalent inhibitor, were evaluated in 88 patients with MSI and/or deficient DNA mismatch repair advanced solid tumors. RO7589831 was administered once daily (150 mg), twice daily (BID; 150–1,000 mg) or three-times daily (TID; 200–600 mg). Primary objectives were to evaluate safety and tolerability, and identify the recommended phase 2 dose and schedule (RP2D). Secondary objectives included evaluation of antitumor activity (end points: disease control rate (DCR), objective response rate (ORR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS)). One dose-limiting toxicity of grade 2 nausea occurred in the 600-mg TID cohort; however, the maximum tolerated dose was not identified per protocol. Treatment-emergent adverse events (TEAEs) occurring in ≥10% were mostly grade 1–2; events in ≥30% were nausea (54.5%, 48/88; grade 3+: 2.3%, 2/88), diarrhea (43.2%, 38/88; grade 3+: 1.1%, 1/88), fatigue (39.8%, 35/88; grade 3+: 2.3%, 2/88), anemia (37.5%, 33/88; grade 3+: 11.4%, 10/88), and vomiting (30.7%, 27/88, grade 3+: 1.1%, 1/88). TEAEs leading to RO7589831 discontinuation were uncommon (3.4%, 3/88). No grade 5 TEAEs occurred. The DCR among MSI efficacy-evaluable patients was 74.2% (49/66). Seven patients achieved confirmed RECIST v.1.1 partial responses (ORR 10.6%, 7/66); median DOR was 10.2+ months. Among MSI efficacy-evaluable patients, median PFS was 6.7 months (95% CI 4.1–8.5); median OS was 17.6 months (95% CI 17.6–not estimable). Although direct target engagement in tumor tissue could not be demonstrated, exploratory analyses of ctDNA molecular response and FDG-PET metabolic response supported biological activity. The 150-mg and 600-mg BID doses were selected as RP2Ds for dose optimization. These data suggest that RO7589831 has a manageable safety profile and warrants further clinical testing. ClinicalTrials.gov identifier: NCT06004245 .
- 29 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (11) , 4068-4078
Open AccessWerner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial
Werner syndrome helicase (WRN) is a synthetic lethal target for microsatellite instability (MSI) cancers. In part 1 of this ongoing first-in-human, phase 1 trial, escalating doses of RO7589831 (VVD-133214), a first-in-class, WRN covalent inhibitor, were evaluated in 88 patients with MSI and/or deficient DNA mismatch repair advanced solid tumors. RO7589831 was administered once daily (150 mg), twice daily (BID; 150–1,000 mg) or three-times daily (TID; 200–600 mg). Primary objectives were to evaluate safety and tolerability, and identify the recommended phase 2 dose and schedule (RP2D). Secondary objectives included evaluation of antitumor activity (end points: disease control rate (DCR), objective response rate (ORR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS)). One dose-limiting toxicity of grade 2 nausea occurred in the 600-mg TID cohort; however, the maximum tolerated dose was not identified per protocol. Treatment-emergent adverse events (TEAEs) occurring in ≥10% were mostly grade 1–2; events in ≥30% were nausea (54.5%, 48/88; grade 3+: 2.3%, 2/88), diarrhea (43.2%, 38/88; grade 3+: 1.1%, 1/88), fatigue (39.8%, 35/88; grade 3+: 2.3%, 2/88), anemia (37.5%, 33/88; grade 3+: 11.4%, 10/88), and vomiting (30.7%, 27/88, grade 3+: 1.1%, 1/88). TEAEs leading to RO7589831 discontinuation were uncommon (3.4%, 3/88). No grade 5 TEAEs occurred. The DCR among MSI efficacy-evaluable patients was 74.2% (49/66). Seven patients achieved confirmed RECIST v.1.1 partial responses (ORR 10.6%, 7/66); median DOR was 10.2+ months. Among MSI efficacy-evaluable patients, median PFS was 6.7 months (95% CI 4.1–8.5); median OS was 17.6 months (95% CI 17.6–not estimable). Although direct target engagement in tumor tissue could not be demonstrated, exploratory analyses of ctDNA molecular response and FDG-PET metabolic response supported biological activity. The 150-mg and 600-mg BID doses were selected as RP2Ds for dose optimization. These data suggest that RO7589831 has a manageable safety profile and warrants further clinical testing. ClinicalTrials.gov identifier: NCT06004245 .
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows chemo-proteomic analysis of VVD-065 selectivity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows chemo-proteomic analysis of VVD-065 selectivity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows cysteine-directed selectivity analysis of VVD-065 and related compounds
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows cysteine-directed selectivity analysis of VVD-065 and related compounds
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows VVD-065 enhances NRF2 ubiquitination by increasing the KEAP1- CUL3 protein-protein interaction
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows VVD-065 enhances NRF2 ubiquitination by increasing the KEAP1- CUL3 protein-protein interaction
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Method 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows synthesis routes of compounds
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Method 1 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows synthesis routes of compounds
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows additional analysis of the tumor growth inhibition study in the KLN205 syngeneic model, and evaluation of the tolerability of VVD-065 in combination with chemotherapy in patient-derived xenograft models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows additional analysis of the tumor growth inhibition study in the KLN205 syngeneic model, and evaluation of the tolerability of VVD-065 in combination with chemotherapy in patient-derived xenograft models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Method 2 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Method 2 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows TGI effects of VVD-065 and NRF2 genetic ablation in a variety of cell line derived xenograft models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth
Shows TGI effects of VVD-065 and NRF2 genetic ablation in a variety of cell line derived xenograft models